Last reviewed · How we verify

NCT04821518

The Use of Samsung Health and ECG M-Trace Base II Applications in the Secondary Prevention After Stroke

Completed Last updated 29 March 2021
What this trial tests

trial in Mobile Applications in 52 participants. Completed in 1 March 2021.

Timeline
15 November 2020
Primary endpoint
1 March 2021
1 March 2021

Quick facts

Lead sponsorPoznan University of Medical Sciences
StatusCompleted
Study typeOBSERVATIONAL
Enrollment52
Start date15 November 2020
Primary completion1 March 2021
Estimated completion1 March 2021
Sites1 location across Poland

Conditions studied

Sponsor

Poznan University of Medical Sciences

Who can join

Adults 42 to 65, any sex, with Mobile Applications or Secondary Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study was to quantitatively assess the risk factors that may affect the re-occurrence of a CVD event and the use of a commercially available mobile application Samsung Health for the assessment of parameters of exercise tolerance and the ECG M-Trace Base II application for the assessment of cardiological parameters.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The Use of Samsung Health and ECG M-Trace Base II Applications for the Assessment of Exercise Tolerance in the Secondary Prevention in Patients after Ischemic Stroke.
    Lucki M, Chlebuś E, Wareńczak A, Lisiński P. · · 2021 · cited 1× · PMID 34071967 · DOI 10.3390/ijerph18115753

Verify or expand the search:

Other recruiting trials for Mobile Applications

Currently open trials in the same condition.

Other Poznan University of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04821518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing